Dermapharm Holding SE : Strong profitability in Q3, adjusted EBITDA guidance raised, as expected
>Q3 a positive surprise on adjusted EBITDA - While Q3 was slightly lower on revenues (€ 242.5m vs our estimate of € 243.4m and consensus, company-collected, of € 246.7m), adjusted EBITDA came in at € 90.8m vs our forecast of € 86.4m and the consensus of € 83.2m. With all divisions having contributed to this we note in particular that Herbal extracts benefitted from a special effect related to the valuation of Fyta (divisional adjusted EBITDA was € 2m better than our f...Dermapharm Holding SE. Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.